Table of Contents
Introduction
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist, also called a GnRH receptor antagonist or LHRH receptor antagonist. It is used as relugolix alone under the brand name Orgovyx for adult patients with advanced prostate cancer. Relugolix is also present in the combination product Myfembree, which contains relugolix, estradiol, and norethindrone acetate for selected gynecological indications such as heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis.
The main pharmacological action of relugolix is competitive blockade of GnRH receptors in the anterior pituitary gland. By blocking these receptors, relugolix reduces secretion of luteinizing hormone and follicle-stimulating hormone. This leads to reduced sex hormone production from the gonads.
In males, reduced LH secretion decreases testicular testosterone production. This produces androgen deprivation, which is useful in advanced prostate cancer because many prostate cancer cells depend on androgen receptor signaling for growth and survival.
In females, reduced LH and FSH secretion decreases ovarian estradiol and progesterone production. This reduces hormonal stimulation of estrogen-dependent conditions such as uterine fibroids and endometriosis. In Myfembree, estradiol and norethindrone acetate are added as “add-back” therapy to reduce hypoestrogenic adverse effects while maintaining symptom control.
For exam purposes, relugolix should be remembered as an oral GnRH receptor antagonist that rapidly suppresses LH, FSH, testosterone, estradiol, and progesterone without the initial hormone flare seen with GnRH agonists such as leuprolide.
Mechanism of Action (Step-wise)
Step 1: The hypothalamus releases GnRH
The hypothalamus normally releases gonadotropin-releasing hormone in pulses. GnRH travels through the hypophyseal portal circulation to the anterior pituitary gland.
Step 2: GnRH activates pituitary GnRH receptors
GnRH binds to GnRH receptors on pituitary gonadotroph cells. This receptor activation stimulates release of two important gonadotropins: luteinizing hormone and follicle-stimulating hormone.
Step 3: LH and FSH regulate gonadal hormone production
In males, LH stimulates Leydig cells in the testes to produce testosterone. FSH supports spermatogenesis through effects on Sertoli cells. In females, FSH promotes ovarian follicular development and estrogen synthesis, while LH supports ovulation and corpus luteum function.
Step 4: Sex hormones drive disease activity in certain conditions
Testosterone supports androgen receptor signaling in prostate cancer cells. Estradiol supports growth and inflammatory activity in estrogen-dependent gynecological conditions such as uterine fibroids and endometriosis.
Step 5: Relugolix competitively blocks GnRH receptors
Relugolix binds to GnRH receptors in the anterior pituitary and blocks endogenous GnRH from activating them. This is the central molecular mechanism of relugolix. The Orgovyx label describes relugolix as a nonpeptide GnRH receptor antagonist that competitively binds pituitary GnRH receptors.
Step 6: LH and FSH secretion decrease
When GnRH receptor signaling is blocked, pituitary secretion of LH and FSH falls. This occurs rapidly because relugolix directly blocks the receptor rather than first stimulating it.
Step 7: Testosterone production decreases in males
In prostate cancer treatment, reduced LH lowers testicular testosterone synthesis. This produces medical androgen deprivation and reduces androgen receptor activation in prostate cancer cells.
Step 8: Castrate testosterone levels are achieved
The goal in advanced prostate cancer is to reduce testosterone to castrate levels. Lower testosterone reduces androgen-dependent tumor growth signaling and helps control disease progression.
Step 9: Estradiol and progesterone production decrease in females
In females, suppression of LH and FSH lowers ovarian estradiol and progesterone production. This reduces hormonal stimulation of fibroid tissue and endometriotic implants.
Step 10: Uterine fibroid bleeding decreases
Uterine fibroids are hormone-sensitive smooth muscle tumors of the uterus. By reducing ovarian hormone stimulation, relugolix decreases fibroid-related endometrial bleeding activity. In Myfembree, add-back estradiol and norethindrone acetate help reduce hypoestrogenic bone loss and vasomotor symptoms while maintaining bleeding control.
Step 11: Endometriosis-associated pain decreases
Endometriosis is an estrogen-dependent inflammatory disorder. Lower estradiol levels reduce stimulation of ectopic endometrial-like lesions, inflammation, prostaglandin-related pain signaling, and pelvic pain symptoms.
Step 12: No initial hormone flare occurs
A key advantage of relugolix over GnRH agonists is absence of initial flare. GnRH agonists first stimulate GnRH receptors, causing a temporary rise in LH, FSH, testosterone, or estradiol before receptor downregulation. Relugolix directly blocks the receptor, so it suppresses hormones without this initial surge.
Step 13: Effects are reversible after discontinuation
Because relugolix is an oral receptor antagonist, hormone suppression can reverse after treatment is stopped. LH, FSH, testosterone, and ovarian hormones may recover over time, depending on patient factors and duration of therapy.
Step 14: Relugolix does not directly block androgen or estrogen receptors
Relugolix does not work by directly blocking androgen receptors in prostate cancer cells or estrogen receptors in reproductive tissues. It works upstream at the pituitary gland by reducing gonadotropin-driven hormone production.
Step 15: Final therapeutic outcome
The final therapeutic outcome is controlled suppression of gonadal sex hormone production. In advanced prostate cancer, this produces androgen deprivation. In relugolix-containing gynecological therapy, this reduces estrogen-dependent bleeding and pain while add-back hormones help improve tolerability.
Pharmacokinetics
Relugolix is administered orally. As Orgovyx, the recommended regimen for advanced prostate cancer begins with a 360 mg loading dose on Day 1, followed by 120 mg once daily at approximately the same time each day.
As Myfembree, relugolix is given in a fixed-dose oral combination tablet with estradiol and norethindrone acetate once daily. The recommended total duration of Myfembree treatment is 24 months because of the risk of continued bone mineral density loss.
Relugolix may be taken with or without food. Tablets should be swallowed whole and taken consistently because missed doses can reduce continuous hormone suppression.
Relugolix is a substrate of P-glycoprotein. This is an important drug interaction point. P-glycoprotein inhibitors may increase relugolix exposure, while combined P-glycoprotein and strong CYP3A inducers may reduce relugolix exposure and decrease effectiveness.
Relugolix is metabolized through multiple pathways, including CYP3A involvement. Because of this, medication review is important before starting therapy, especially in patients taking anticonvulsants, rifampin-like antibiotics, certain antivirals, azole antifungals, or other strong enzyme/transporter modulators.
Relugolix has a long enough half-life to support once-daily dosing. In the Myfembree label, after administration of a single dose, the mean terminal half-life of relugolix is reported as approximately 61.5 hours.
Because relugolix suppresses sex hormones, pharmacodynamic monitoring depends on the indication. In prostate cancer, testosterone and PSA response may be monitored. In gynecological use, bleeding pattern, pain response, pregnancy status, bone health, and adverse effects are clinically important.
Clinical Uses
Relugolix as Orgovyx is used for adult patients with advanced prostate cancer. Its purpose is medical androgen deprivation by lowering testosterone production. This helps reduce androgen receptor stimulation in androgen-sensitive prostate cancer cells.
Relugolix is useful as an oral alternative to injectable androgen deprivation therapies. Unlike GnRH agonists, it does not produce an initial testosterone flare, which can be clinically relevant in advanced prostate cancer patients at risk of symptom worsening.
Relugolix is also used as part of Myfembree, a combination product containing relugolix, estradiol, and norethindrone acetate. Myfembree is used in selected patients for heavy menstrual bleeding associated with uterine fibroids and for moderate to severe pain associated with endometriosis.
In uterine fibroids, relugolix reduces ovarian hormone stimulation, helping decrease heavy menstrual bleeding. Estradiol and norethindrone acetate are included to reduce excessive hypoestrogenic effects and protect against bone loss.
In endometriosis, relugolix reduces estrogen-driven stimulation of ectopic endometrial-like tissue. This helps reduce dysmenorrhea, non-menstrual pelvic pain, and other endometriosis-associated pain symptoms.
Relugolix is not chemotherapy, not an antiandrogen receptor blocker, not an aromatase inhibitor, and not an emergency pain medicine. It is an oral pituitary GnRH receptor antagonist used for hormone suppression.
Adverse Effects
The adverse effects of relugolix depend on whether it is used alone as Orgovyx or in combination with estradiol and norethindrone acetate as Myfembree.
With relugolix alone in advanced prostate cancer, adverse effects mainly reflect androgen deprivation. Common adverse reactions include hot flushes, musculoskeletal pain, fatigue, constipation, diarrhea, increased glucose, increased triglycerides, decreased hemoglobin, and increased liver enzymes.
Testosterone suppression can also cause reduced libido, erectile dysfunction, mood changes, weight changes, anemia, reduced muscle mass, and reduced bone mineral density over time. These effects are common concepts in androgen deprivation therapy.
QT or QTc interval prolongation is an important warning with androgen deprivation therapy. Caution is needed in patients with congenital long QT syndrome, electrolyte abnormalities, heart disease, or drugs that prolong the QT interval.
Embryo-fetal toxicity is important. Relugolix can cause fetal harm based on its mechanism of hormone suppression. Pregnancy should be avoided where relevant, and contraception guidance should be followed according to the specific product.
With Myfembree, adverse effects include both relugolix-related hypoestrogenic effects and estrogen/progestin-related risks. The combination product carries important warnings related to thromboembolic disorders and vascular events because it contains estradiol and norethindrone acetate.
Bone mineral density loss is a major concern in gynecological use. Relugolix lowers estradiol, and low estrogen can reduce bone density. Add-back therapy reduces but does not completely eliminate this concern, which is why treatment duration is limited.
Mood changes, depression, suicidal ideation, liver enzyme elevations, gallbladder disease, elevated blood pressure, changes in menstrual bleeding pattern, alopecia, and hypersensitivity reactions are also clinically important with relugolix-containing gynecological therapy.
Relugolix-containing products are contraindicated or avoided in specific situations depending on formulation, including pregnancy, severe hypersensitivity, certain thrombotic risks for combination therapy, hepatic impairment or disease for Myfembree, and important interacting medications.
Comparative Analysis
Relugolix is commonly compared with GnRH agonists such as leuprolide, goserelin, triptorelin, and histrelin.
Compared with GnRH agonists, relugolix directly blocks pituitary GnRH receptors. GnRH agonists initially stimulate the receptor before downregulation, causing a temporary hormone flare. Relugolix avoids this flare because it is an antagonist.
Compared with leuprolide in prostate cancer, relugolix is taken orally once daily, while leuprolide is given as an injectable depot formulation. Oral dosing is convenient but requires strict adherence.
Compared with degarelix, relugolix is also a GnRH antagonist. Degarelix is given by subcutaneous injection, while relugolix is oral. Both avoid testosterone flare, but their route and dosing schedules differ.
Compared with antiandrogens such as bicalutamide, enzalutamide, apalutamide, and darolutamide, relugolix works upstream by reducing testosterone production. Antiandrogens block androgen receptor signaling at the receptor level.
Compared with abiraterone, relugolix has a different endocrine target. Abiraterone inhibits CYP17 and reduces androgen synthesis from testes, adrenal glands, and tumor tissue. Relugolix suppresses pituitary LH and thereby reduces testicular testosterone production.
Compared with elagolix, relugolix shares the GnRH antagonist class. Elagolix is used for endometriosis-associated pain as Orilissa, while relugolix is used in prostate cancer as Orgovyx and in combination gynecological therapy as Myfembree. Both suppress gonadotropins without initial flare.
Compared with aromatase inhibitors, relugolix reduces ovarian estrogen production by suppressing LH and FSH, while aromatase inhibitors block peripheral estrogen synthesis from androgens. Their mechanisms and indications differ.
Compared with surgery, relugolix provides medical hormone suppression. Orchiectomy permanently removes the main source of testosterone, while relugolix produces reversible medical androgen deprivation. Surgical treatment for fibroids or endometriosis physically removes or treats lesions, while relugolix provides medical hormonal control.
MCQs
- Relugolix belongs to which pharmacological class?
a) GnRH receptor antagonist
b) GnRH receptor agonist
c) Aromatase inhibitor
d) Androgen receptor blocker
Answer: a) GnRH receptor antagonist
- Relugolix acts primarily at which site?
a) Anterior pituitary GnRH receptors
b) Androgen receptors in prostate cells only
c) Estrogen receptors in breast tissue only
d) Dopamine D2 receptors
Answer: a) Anterior pituitary GnRH receptors
- Blocking GnRH receptors reduces secretion of:
a) LH and FSH
b) Insulin and glucagon
c) TSH and prolactin only
d) Cortisol and aldosterone
Answer: a) LH and FSH
- In males, reduced LH secretion mainly decreases:
a) Testosterone production
b) Thyroxine production
c) Insulin release
d) Aldosterone secretion
Answer: a) Testosterone production
- In females, relugolix reduces ovarian production of:
a) Estradiol and progesterone
b) Cortisol and adrenaline
c) Dopamine and serotonin
d) Insulin and glucagon
Answer: a) Estradiol and progesterone
- Relugolix differs from GnRH agonists because it:
a) Does not cause initial hormone flare
b) First increases testosterone in all patients
c) Directly blocks bacterial ribosomes
d) Directly inhibits aromatase enzyme
Answer: a) Does not cause initial hormone flare
- Relugolix alone is marketed for advanced prostate cancer as:
a) Orgovyx
b) Orilissa
c) Zoladex
d) Lupron
Answer: a) Orgovyx
- Myfembree contains relugolix with:
a) Estradiol and norethindrone acetate
b) Testosterone and progesterone
c) Leuprolide and bicalutamide
d) Metformin and insulin
Answer: a) Estradiol and norethindrone acetate
- In prostate cancer, relugolix produces therapeutic benefit mainly by:
a) Androgen deprivation
b) Direct DNA alkylation
c) HER2 blockade
d) EGFR-MET receptor degradation
Answer: a) Androgen deprivation
- In endometriosis, relugolix helps reduce pain mainly by:
a) Lowering ovarian estradiol stimulation
b) Increasing estrogen production
c) Blocking bacterial cell wall synthesis
d) Increasing prostaglandin synthesis
Answer: a) Lowering ovarian estradiol stimulation
- Which transporter interaction is important for relugolix?
a) P-glycoprotein
b) Dopamine transporter only
c) Sodium-glucose cotransporter only
d) Serotonin transporter only
Answer: a) P-glycoprotein
- Which ECG-related warning is important with relugolix androgen deprivation therapy?
a) QT/QTc interval prolongation
b) Complete protection from arrhythmias
c) Mandatory heart block in all patients
d) Shortened QT interval only
Answer: a) QT/QTc interval prolongation
- Which adverse effect is common with relugolix in prostate cancer therapy?
a) Hot flushes
b) Severe ototoxicity
c) Gingival hyperplasia
d) Severe hypoglycemia in every patient
Answer: a) Hot flushes
- Which safety concern is important with relugolix-containing gynecological therapy?
a) Bone mineral density loss
b) Permanent hearing loss
c) Dopamine toxicity
d) Acute bacterial pneumonia
Answer: a) Bone mineral density loss
- Which statement best describes relugolix?
a) It competitively blocks pituitary GnRH receptors and suppresses LH, FSH, and gonadal sex hormones
b) It directly blocks androgen receptors only
c) It irreversibly inhibits cyclooxygenase
d) It stimulates soluble guanylate cyclase
Answer: a) It competitively blocks pituitary GnRH receptors and suppresses LH, FSH, and gonadal sex hormones
FAQs
What is the mechanism of action of relugolix?
Relugolix competitively blocks GnRH receptors in the anterior pituitary gland. This reduces LH and FSH secretion, which lowers testosterone production in males and estradiol/progesterone production in females.
Is relugolix a GnRH agonist or antagonist?
Relugolix is a GnRH receptor antagonist. It directly blocks pituitary GnRH receptors and does not cause the initial hormone flare seen with GnRH agonists.
What is the brand name of relugolix?
Relugolix alone is marketed as Orgovyx for advanced prostate cancer. Relugolix is also included in the combination product Myfembree with estradiol and norethindrone acetate.
What is relugolix used for?
Relugolix is used as Orgovyx for adult patients with advanced prostate cancer. In combination with estradiol and norethindrone acetate as Myfembree, it is used for selected gynecological conditions such as heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis.
Why does relugolix not cause testosterone flare?
Relugolix is a receptor antagonist, so it blocks GnRH receptors immediately. GnRH agonists first stimulate the receptor before suppressing it, which causes a temporary testosterone flare.
Does relugolix lower estrogen?
Yes. In females, relugolix lowers LH and FSH, which reduces ovarian estradiol and progesterone production. This helps in estrogen-dependent conditions but can also cause hypoestrogenic adverse effects.
What are common adverse effects of relugolix?
Common adverse effects depend on the product and indication. In prostate cancer therapy, hot flushes, fatigue, musculoskeletal pain, constipation, diarrhea, increased glucose, increased triglycerides, decreased hemoglobin, and liver enzyme changes may occur. In gynecological therapy, bone mineral density loss, mood changes, bleeding pattern changes, and estrogen/progestin-related risks are important.
How is relugolix different from leuprolide?
Relugolix is an oral GnRH antagonist that directly blocks GnRH receptors. Leuprolide is an injectable GnRH agonist that initially stimulates GnRH receptors and can cause a temporary hormone flare before suppression.
References
Goodman & Gilman’s The Pharmacological Basis of Therapeutics
Katzung Basic & Clinical Pharmacology
